Shots:

• AstraZeneca to get exclusive promotion rights in China including Taiwan- Hong Kong- Singapore- Malaysia for Luye’s Xuezhikang capsules. Luye Pharma will retain its IPR- commercialization rights- asset rights & registration permit rights
• The focus of the agreement is to promote Xuezhikang in cardiovascular disorders and strengthening Luye’s footprints in cardiology- with its further expansion in the US and EU
• Xuezhikang is a lipid-regulating candidate used for maintaining abnormal blood lipids and is evaluated in P-II trial for patients with LDL-C

Ref:  Luye Pharma | Image: AstraZeneca